

Ulm, Germany, November 18, 2021

Sartorius Opens Cell Culture Technology Center in the Scientific Hub of Ulm, Germany

The life science group Sartorius officially opened its Cell Culture Technology Center at Science Park III, a major hub for cutting-edge research and scientific discovery near many of Germany's top universities. Around 120 employees work at this Sartorius facility featuring special laboratories and covering 6,000 square meters, some 65,000 square feet, to develop cell lines and optimize cell culture media, which manufacturers of biologics need to produce advanced medicines and vaccines. Sartorius has invested around 30 million euros on the whole in its Ulm-based Cell Culture Technology Center. The Mayor of Ulm, Gunter Czisch, and the President of the University of Ulm, Prof. Michael Weber, joined the opening ceremony that was held virtually due to the pandemic.

"Our Cell Culture Technology Center enables us to support manufacturers of biopharmaceuticals even more efficiently so that innovative medicines reach patients faster while helping us to drive growth in a key market of tomorrow. For this reason, we will be looking to recruit new employees in the future as well," said Hugo de Wit, Head of Cell Culture Technologies at Sartorius and Managing Director of the Ulm site. Currently, Sartorius is offering more than a dozen job positions in Ulm and around 1,300 worldwide.

As a leading international partner of life science research and the biopharmaceutical industry, Sartorius in Ulm develops cell lines and protein production processes, licenses technologies for manufacturing proteins, and offers cell culture media. Proteins produced by living cells are used in the discovery, development, and production of biopharmaceutical medicines and vaccines.

A Profile of Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2020, the company earned sales revenue of some 2.34 billion euros. At the end of 2020, nearly 11,000 people were employed at the Group's approximately 60 manufacturing and sales sites, serving customers around the globe.

Contact

Timo Lindemann | Press Spokesman

+49 (0)551.308.4724

timo.lindemann@sartorius.com